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Abstract
Purpose:

The aim of this study was to evaluate the association between total brachial
artery reactivity (TBAR) and the cumulative risk of incident heart failure
(HF), HF with reduced ejection fraction (HFrEF), and HF with preserved
ejection fraction (HFpEF) in a community-based study.

Methods:

Sample included 5,499 participants (45-84 years of age) from the MultiEthnic Study of Atherosclerosis who were free of cardiovascular disease at
baseline. Brachial artery ultrasound was performed after five minutes of
cuff occlusion at the right forearm. TBAR was calculated as the difference
between maximum and minimum brachial artery diameters following cuff
release, divided by the minimum diameter multiplied by 100%. A
dichotomous TBAR variable was created based on the median value (below
or above 7.9%). Participants with EF≤40% were considered HFrEF and
those with EF ≥ 50% were considered HFpEF. Cox proportional hazards
regression models were used to calculate hazard ratios (HR) and 95%
confidence intervals (CI).

Results:

Over a mean follow-up period of 12.5 years, incident HF was diagnosed in
250 participants; 98 classified as HFrEF, 106 as HFpEF, and 46 with
unknown or borderline EF (41-49%). Crude analysis revealed that those
with TBAR below the median have significantly higher risk of HF (HR
1.46; 95% CI 1.13-1.88, p<0.01) and HFrEF (HR 1.61; 95% CI 1.07-2.43,
p<0.05). Following adjustment for known HF risk factors (e.g. age, gender,
race, blood pressure, others), these relationships were no longer statistically
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significant. Borderline significant results were revealed in those with
HFpEF (HR 1.43; 95% CI 0.97-2.12, p=0.06). Kaplan-Meier curves suggest
significantly lower risks of developing HF and HFrEF in those with TBAR
above the median (log-rank p≤0.05 for both). When examined as a
continuous variable, with a cut point of 50% for EF, every 1-standard
deviation (9.7%) increase in TBAR resulted in a 19% and 29% decrease in
risk of HF (p<0.05) and HFrEF (p=0.05), respectively.
Conclusion:

Lower TBAR values were associated with higher rates of incident HF and
HFrEF, suggesting a possible role of endothelial dysfunction in HF
pathogenesis. The impact of other known HF risk factors may mediate this
relationship, thus further research is warranted.

1

Chapter One: Introduction
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The American College of Cardiology Foundation (ACCF)/ American Heart Association
(AHA) defines heart failure (HF) as “a complex clinical syndrome that results from any structural
or functional impairment of ventricular filling or ejection of blood” (1). The abnormalities
associated with this syndrome result in reduced cardiac output and/or elevated intracardiac
pressures (2). Consequently, the heart is unable to pump blood to the body at a rate matching its
needs. Based on systolic function measured by left ventricular ejection fraction (LVEF), HF can
be classified into two major subtypes: heart failure with reduced ejection fraction (HFrEF), and
heart failure with preserved ejection fraction (HFpEF). The two subtypes display marked
differences in etiology, risk factors, and response to treatment (3-5).
It is estimated that HF affects 1 to 3% of the population worldwide and can increase to
10% or more in populations over 70 years old (4-6); the number of persons is projected to increase
46% by 2030 (7). According to statistics approximately one-half of the patients with HF have
HFrEF and the other half have HFpEF (7, 8). Despite major advances in HF management and
treatment, mortality remains high (5, 6).
Evidence suggest that endothelial dysfunction may be a phenotypic expression of HF and
may play a role in its pathogenesis (8-12). Total brachial artery reactivity (TBAR) is a novel
noninvasive measurement that evaluates endothelial function using ultrasound imaging. This
measurement uses a baseline brachial artery diameter following cuff deflation and compensates
for the absence of a stereotactic device, restricting errors associated with ultrasound probe
displacement (13). TBAR has been found to be an independent predictor of incident coronary heart
disease (CHD) events.
This chapter includes pertinent background information relating to HF and TBAR. A
focused review of the existing literature regarding the relationship between these variables is also
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included. The chapter concludes with the purpose and significance of the research, the project
description, and limitations inherent to the study design.

BACKGROUND
HEART FAILURE
HF is considered a growing public health problem with a prevalence over 5.8 million adults
in the United States (U.S) and approximately 37.7 million worldwide (5, 14). Even though these
estimates vary depending on the study population and the diagnosis criteria, the prevalence of HF
is approximately 1 to 3% and increases to 10% with advancing age (4-6, 14). The increased
prevalence of HF over time may reflect a combination of growth of the aging population, changes
in the prevalence of risk factors, and improvements in the recognition, management, and treatment
of HF (14, 15).
Annually in the U.S more than 550,000 individuals are diagnosed with incident HF, and it
is estimated that 1 in 5 men and women over 40 years of age will develop HF during their lifetime
(14, 16). According to the Framingham Heart Study (FHS), the incidence of HF is about 10 per
1,000 person-years in those >65 years of age, but it seems to be stabilizing, or even decreasing in
women in which the incidence declined about 30% between 1950–1969 and 1990–1999 (14-16).
Data from the Atherosclerosis Risk in Communities (ARIC) showed the lowest HF incidence in
white women (3.4 per 1,000 person-years) and the highest in black men (9.1 per 1,000 personyears) (14). However, these differences were attenuated after adjustment for risk factors, such as
diabetes, and hypertension.
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Additionally, HF is considered a leading cause of hospitalization among the elderly, and
one of the most frequent causes of urgent hospitalizations in the Medicare population (5, 17).
Although efforts to find effective therapeutics have reduced the prevalence of rehospitalizations
to 30-50%, the mortality rates remain high (2, 5, 6, 14). According to statistics, the mortality rate
in patients who are hospitalized is approximately 4% and increases to 10% within one-month of
discharge (17). Based on the FHS, the 30-day, 1-year, and 5-year mortality, is nearly 10%, 20–
30%, and 45–60%, respectively (14-16). HF has extensive implications not only in terms of
mortality and morbidity but also confers a considerable burden to the health-care system (2, 4, 5,
14, 18). The World Bank estimates that the global economic cost of managing HF is about $108
billion annually (4) and in the U.S, it is expected to rise from $20.9 billion in 2012 to $53.1 billion
by 2030 (5).
The diagnosis of HF is challenging since it is based on an integration of the patient’s
history, evaluation of signs and symptoms, physical examination, imaging data, and laboratory
findings, that require judgment and experience (5, 17). In 1971 the FHS established clinical criteria
for HF diagnosis according to physical examination and physician adjudication (5). A diagnosis
of definite HF required the combination of at least two major criterion (e.g., rales, S3 gallop, neckvein distension), or one major criterion and two minor criterion (e.g., ankle edema, dyspnea, etc.)
(19). However, depending on the clinical and epidemiological studies, definitions and diagnostic
criteria of HF vary widely and are prone to misclassification (5).
The HF entity has different characteristics depending on age, sex, race/ethnicity, LVEF,
and HF etiology. Presentation of HF signs and symptoms differs widely and range from those with
severe LV systolic dysfunction and low cardiac output to those with severe hypertension and
normal or near-normal LV systolic function (4). As such, EF has been considered important in
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classification of patients with HF. Based on the ACCF/AHA guidelines (1) HFrEF, also referred
to as systolic HF, is defined “as the clinical diagnosis of HF with an EF ≤40%”, and HFpEF,
referred to as diastolic HF, “as HF with an EF ≥50%”; those with an EF between 40-49% are
considered borderline.
Several studies have estimated that among individuals with HF, approximately half of the
events are characterized by reduced EF and the other half by preserved EF (1, 17, 20). The overall
number of patients living with HF seems to be increasing over time, because of aging of the
population, general population growth, and improved survival (5, 21). However, the prevalence of
HFpEF is higher than that of HFrEF. According to data from the AHA, the proportion of patients
hospitalized with HFpEF increased from 33% in 2005 to 39% in 2010 (5). The two subtypes
exhibit marked differences in etiology, risk factors, and response to treatment (3, 20). Those who
develop HFpEF tend to be older women, with a history of hypertension (HTN) or atrial fibrillation
(AF), and those with HFrEF tend to be males, with a history of cardiomyopathy and myocardial
infarction (MI) (3, 14). Despite the advances in treatments, strategies that have demonstrated to be
effective among those with HFrEF are ineffective among those with HFpEF (1, 14). For this
reason, there has been an increased interest in identifying better diagnosis, phenotype
characterization, and novel treatments between the two subtypes.
TOTAL BRACHIAL ARTERY REACTIVITY
The brachial artery responds to shear stress induced by increasing blood flow during
reactive hyperemia in a similar way to the coronary arteries; as such it is commonly used as a
surrogate for evaluating coronary endothelial function (22). The total brachial artery reactivity
(TBAR) is a noninvasive measurement that evaluates endothelial function using ultrasound
imaging. It relies on obtaining a baseline diameter of the artery following cuff deflation. After 5
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minutes of occlusion with a blood pressure cuff to induce forearm ischemia, TBAR is determined
as the maximal brachial artery diameter compared to a baseline measurement (13). Although the
baseline artery diameter is commonly measured before cuff inflation, this method might
compensate for the absence of a stereotactic device, limiting the errors associated with ultrasound
probe displacement (13). In a study comparing pre-occlusion, occlusion, and post-occlusion
baseline brachial artery measurements, there were no significant differences between them; in
addition, peak dilation values were not significantly different when calculated from pre-occlusion,
occlusion or post-occlusion baseline diameters (23).
The expected response of a healthy endothelium is an increase in brachial artery diameter,
secondary to the endogenous release of nitric oxide (NO) (9, 24-26). On the other hand, reduced
bioavailability of NO and increased formation of reactive oxygen species (ROS) within the
vascular wall are markers of endothelial dysfunction (9, 24, 27). Previous studies have found a
strong association between endothelial dysfunction measured by flow-mediated dilation (FMD),
incident cardiovascular disease (CVD) events, and heart failure (12, 22, 25, 28, 29). Since
attenuated vascular responses seem to occur prior to the development of atherosclerosis, the early
assessment of endothelial function has become appealing to evaluate cardiovascular risk (25, 26,
30).
In a study conducted by Polak et al. (13) using data from the Multi-Ethnic Study of
Atherosclerosis (MESA), increased TBAR values were associated with a 22% lower risk of
incident CHD events per SD increase (9.7 SD) (HR 0.78; 95% CI 0.67-0.91, p = 0.001). In
addition, they found that a TBAR above the median of 7.87% was associated with a 31% lower
risk of CHD events (HR 0.69; 95% CI 0.55-0.87, p = 0.001). They concluded that TBAR is an
independent predictor of first time CHD events.
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FOCUSED LITERATURE REVIEW
Evidence suggest that endothelial dysfunction may be a phenotypic expression of HF and
may play a role in the pathogenesis of this entity (8, 9, 12, 31). It is possible that the characteristic
neurohumoral activation in HF might be associated with an imbalance between NO and ROS (27).
Increases in ROS result in decreased bioavailability of NO, negatively impacting the expression
and activation of endothelial NO synthase (eNOS) and subsequent endothelial function (6, 26, 32).
Although TBAR has been associated with increased risk of cardiovascular outcomes in a
community-based study (13), limited information is currently available on the impact of TBAR on
incident HF, HFrEF, and HFpEF.

PURPOSE AND SIGNIFICANCE
Despite the efforts to establish clear differences between HFrEF and HFpEF, the etiology,
pathophysiology, and effective treatments for HFpEF are still unclear. Determining the
relationship between endothelial dysfunction as a potential target and incident HF subtypes may
help to elucidate a better understanding of the complex syndrome that is HF. Thus, the aim of this
study was to investigate whether TBAR was associated with overall incident HF, HFrEF, and
HFpEF in a diverse population-based sample of U.S. adults 45-84 years of age. The research
questions addressed include:
1. Is there an association between TBAR and the cumulative risk of overall incident HF,
and the two HF subtypes?
2. Is TBAR an independent predictor for HF and its subtypes?
3. Is there a significant difference between TBAR values for HFrEF and HFpEF?
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To the extent of our knowledge, this is the first study to examine the association between
TBAR and risk of HF stratified by EF in a population-based sample of U.S. adults who participated
in MESA.

PROJECT DESCRIPTION
The data for this study came from MESA (33), an ongoing, multicenter prospective cohort
study of CVD, sponsored by the National Heart Lung and Blood Institute of the National Institutes
of Health. The MESA study is a diverse, population-based sample of 6,814 men and women aged
45-84, with no history of clinical CVD at baseline. Cox proportional hazards regression models
were used to calculate multivariable adjusted hazard ratios and 95% confidence intervals to
determine the risk of HF overall, HFrEF, and HFpEF according to TBAR values.

LIMITATIONS
1. The sample size was relatively small for those with HF, HFrEF and HFpEF,
limiting the generalizability of the results.
2. TBAR and EF were measured at a single time point, therefore potential changes in
these values over time were not included in the analysis.
3. Time to first HF event was used to define incident HF, resulting in the exclusion of
subsequent HF events with potential changes in EF over time.
4. Those individuals without EF data at the time of their first HF event were included
in the analysis of HF overall, but not when categorized by HF subtypes.
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5. TBAR was measured with an occlusion cuff placed proximal to the ultrasound
probe (upper right forearm), which may indicate that the vasodilatory response is
not mediated exclusively by NO.
6. Some of the covariates used for the analysis are subject to recall bias and self-report
bias.
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According to the American Heart Association (AHA) heart failure (HF) is a “complex
clinical syndrome that results from any structural or functional impairment of ventricular filling or
ejection of blood” (1). As a result, the heart is incapable of providing sufficient blood flow to meet
metabolic demands or to accommodate systemic venous return (2, 3). Although HF results from
injury to the myocardium, this syndrome is characterized by multisystemic abnormalities, and a
complex pattern of neurohumoral changes (4-6). Multiple etiologies have been associated with HF
including ischemic heart disease, hypertension, diabetes, and other less common causes such as
cardiomyopathies, valvular disease, infections, and arrhythmias (2). As heart function decreases,
patients with HF experience numerous symptoms, which include dyspnea from pulmonary
congestion, fatigue, poor exercise tolerance, fluid retention, and edema from impaired venous
return (2, 7).
In HF the underlying injury of functional myocardial cells can result in right ventricular
(RV) dysfunction, left ventricular (LV) dysfunction, or both. Pure right-side HF is uncommon, and
in fact, the most common cause of RV dysfunction is LV dysfunction (2). As the RV fails, the
resultant accumulation of blood in the ventricle leads to elevated right atrial pressure and increased
pressure in the vena cava (superior and inferior) which impairs venous return. Left-side HF can be
classified into two categories based on left ventricular ejection fraction (LVEF): systolic and
diastolic (2, 8). Although different etiologies of HF tend to affect more systolic or diastolic
function, most patients with systolic dysfunction also have a component of diastolic dysfunction.
Ejection fraction (EF) refers to the ratio of the amount of blood ejected from the ventricle
in one heartbeat to the ventricular-end diastolic volume. According with the most recent guidelines
by the American College of Cardiology Foundation (ACCF)/(AHA), HF with reduced EF
(HFrEF), also referred to as systolic HF, is defined as an EF ≤40%, whereas HF with preserved

16

EF (HFpEF), also referred to as diastolic HF, is defined as an EF ≥50%. Those with an EF between
41-49% are considered to have HF with mid-range EF (HFmrEF) (1, 9). These subtypes display
marked differences in etiology, risk factors, and response to treatment (7, 10, 11).
This chapter includes a focused literature review on the terminology of HF, HFrEF, and
HFpEF, diagnosis, pathophysiology, and known risk factors associated with each HF subtype.
Existing literature that has investigated the relationship between endothelial function and HF
overall, HFrEF and HFpEF are also included. It concludes with a summary of the literature and
the explanation of the need for additional research.

TERMINOLOGY
Over the past 20-30 years the classification terminology for HF has evolved considerably,
however, disagreements and uncertainties remain (7). The term HF has been used to refer to those
patients with established chronic heart failure and is limited to stages at which clinical symptoms
are present. During the course of this entity, episodes of worsening symptoms and signs can occur,
resulting in a need for urgent care that may require hospitalization. The term used to define these
exacerbations is acute decompensated HF (12, 13). Congestive heart failure is another term that is
frequently used interchangeably with HF. However, because some patients do not exhibit signs or
symptoms of volume overload, the term HF is preferred over congestive heart failure (1, 14).
Depending on the patient’s disease stage, these terms can be applied to the same patient at different
times (9). It is important to note that HF is not synonymous with cardiomyopathy, since the latter
corresponds to a group of diseases of the myocardium that frequently progress to HF. In that sense
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cardiomyopathy describes structural or functional reasons associated with the development of HF
(1, 7, 9).
Previously, the terms systolic and diastolic dysfunction regardless of EF were used to
classify HF. However, because abnormalities of systolic and diastolic function coexist in most
patients, these terms are no longer appropriate (1, 9, 13). The preferred terminology used today is
HF with reduced EF (HFrEF), and HF with preserved EF (HFpEF) based on LVEF, assessed by
echocardiography. Since patients with HF display a wide variety of signs and symptoms, that range
from severe LV systolic dysfunction and low cardiac output (CO) to severe hypertension and
normal or near-normal LV systolic function, classification based on EF is recommended (11). The
importance of using LVEF as a means to classify HF allows differentiation of underlying
etiologies, demographics, comorbidities, and response to therapies between HF subtypes (1, 9, 13).

DIAGNOSIS
Since HF is defined as a clinical syndrome with many etiologies and not a disease, its
diagnosis relies on a careful patient history and clinical examination (1, 9, 12). Multiple criteria
have been proposed to diagnose HF in epidemiological studies, however, there is not a validated
gold standard (15). These include Framingham (16), Boston (17), Gothenburg (18), and the
European Society of Cardiology criteria (19), all of which rely on a combination of data from the
medical history, physical examination, and radiographic evidence (12, 14). A description of these
four criteria is listed in Table 1 below.
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Table 1. Heart failure diagnostic criteria
Framingham
Boston
Major Criteria
-Paroxysmal nocturnal
dyspnea or orthopnea
-Neck vein distension
-Rales
-Cardiomegaly
-Acute pulmonary
edema
-S3 gallop
-Increased venous
pressure ≥16cm water
-Circulation time ≥25
seconds
-Hepatojugular reflux
Minor Criteria
-Ankle edema
-Night cough
-Dyspnea on exertion
-Hepatomegaly
-Pleural effusion
-Vital capacity
decreased 1/3 from
maximum
-Tachycardia rate of
≥120/min)
Major or Minor
Criterion
-Weight loss ≥4.5 kg in 5
days in response to
treatment

HEART FAILURE
present with 2 major or 1
major and 2 minor criteria

Category I: History
-Rest dyspnea (4pts)
-Orthopnea (4pts)
-Paroxysmal nocturnal
dyspnea
(3 pts)
-Dyspnea on walking on
level (2pts)
-Dyspnea on climbing
(1pt)
Category II: Physical
examination
-Heart rate abnormality
(1-2pts)
-Jugular venous pressure
elevation
(1-2 pts)
-Lung crackles
(1-2pts)
-Wheezing (3 pts)
-Third heart sound
(3 pts)

Gothenburg
Cardiac Score
-History of heart disease
(1-2pts)
-Angina (1-2pts)
-Edema (1pt)
-Nocturnal Dyspnea (1pt)
-Rales (1pt)
Atrial fibrillation (1pt)
Pulmonary Score
-History of Chronic
bronchitis/asthma
(1-2pts)
-Cough, phlegm, or
wheezing (1pt)
-Rhonchi (2pts)
Cardiac and pulmonary
score are calculated and
used to differentiate
cardiac from pulmonary
dyspnea

European Society of
Cardiology
1. Symptoms of
heart failure (at
rest or during
exercise) and
2. Objective
evidence of
cardiac
dysfunction (at
rest) and
3. Response to
treatment
directed
towards heart
failure (in cases in which
diagnosis
is in doubt).
Criteria 1 and 2
should be fulfilled in all
cases.

Category III: Chest
radiography
-Alveolar pulmonary
edema (4 pts)
-Interstitial pulmonary
edema (3 pts)
-Bilateral pleural
effusions (3 pts)
-Cardiothoracic
ratio ≥0.50 (3 pts)
-Upper-zone flow
redistribution (2 pts)
HEART FAILURE
Definite 8-12 pts,
possible 5-7pts, unlikely 4
pts or less

Note. Adapted from “Epidemiology of heart failure” by Roger. Circulation Research. 2013;
113(6): 646–659.
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Mosterd et al. (18) compared six different HF scores, including the Framingham and the
Boston criteria. They found that five out of the six scores (excluding the Men Born in 1913) were
similar in the recognition of HF with a high sensitivity for the detection of definite HF. However,
they concluded that objective measurements of cardiac function might be necessary to accurately
detect early stages of HF. Evidence of an underlying cardiac cause is crucial to the diagnosis of
HF since identification of the specific pathology determines the treatment used (9).
Although these criteria identify HF, they do not differentiate between HF subtypes. The
latest guidelines have suggested the use of LVEF, usually measured using echocardiography,
radionuclide technique, or cardiac magnetic resonance, to classify HF patients as HFrEF or
HFpEF. The 2013 ACCF/AHA guidelines to define HF subtypes uses a LVEF of ≤40% to define
HFrEF and a LVEF of ≥50% to define HFpEF (1). Those patients with a LVEF in the range of 41–
49% are now defined as HFmrEF, and present a combination of mild systolic dysfunction, with
elements of diastolic dysfunction.
Because the diagnosis of HFpEF is largely based on exclusion of noncardiac causes of
symptoms suggestive of HF, patients with HFpEF frequently experience delayed diagnosis and
limited treatment options (7, 9). The 2016 European Society of Cardiology guidelines established
specific criteria to define HFpEF, including:
1. The presence of symptoms and/or signs of HF.
2. Evidence of preserved or normal LVEF (≥50% or 40–49% for HFmrEF).
3. Elevated levels of natriuretic peptides (NPs) (B-type NP >35 pg/mL and/or N-terminal proBNP >125 pg/mL).
4. Objective evidence of other cardiac functional and structural alterations underlying HF.
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PATHOPHYSIOLOGY
HF is caused by a structural and/or functional cardiac abnormality, that results in a reduced
CO and/or elevated intracardiac pressures (9). The etiology of HF is diverse and sometimes there
is overlap between possible categories. Among the most common causes are ischemic heart
disease, hypertension, and diabetes (2). Although in HF there is usually a myocardial abnormality
that causes systolic and/or diastolic ventricular dysfunction, abnormalities of the valves,
pericardium, endocardium, heart rhythm and conduction are not uncommon. Other causes of HF
include cardiomyopathies, infections (e.g., viral myocarditis), toxins (e.g., alcohol), and
arrhythmias (9).
Depending on the etiology, some are more likely to affect systolic or diastolic function.
However, most patients with systolic dysfunction also have a component of diastolic dysfunction
(2). The impairment in LV function, results in a reduction of CO and mean arterial pressure (MAP)
which leads to decreased tissue perfusion (2, 4). In addition, the increased amount of blood in the
ventricle results in increased end-systolic and end-diastolic volumes. Consequently, there is an
elevation of atrial pressure and subsequent elevated pressure in the lungs that forces fluid out of
the pulmonary capillaries. The resultant pulmonary congestion is responsible for the clinical
symptom of dyspnea (2).
RV dysfunction is usually secondary to LV dysfunction. Failure of the RV results in
increased pressure in the vena cava which impairs venous return and subsequent peripheral edema.
These conditions lead to activation of several compensatory mechanisms including the FrankStarling mechanism, neurohumoral activation, and ventricular remodeling (2, 4). Regardless of the
beneficial effects of these mechanisms in early phases of this syndrome, they also play a
detrimental role in the development and subsequent progression of HF.

21

The Frank-Starling mechanism causes an increase in CO to maintain adequate tissue
perfusion. The increased end-diastolic volume causes a stretch in the myocardium that results in
greater force of contraction and subsequent greater CO. However, over time the failing heart is
unable to contract, and this compensatory mechanism is diminished, leading to pulmonary
congestion (2). The second mechanism involves neurohumoral activation to maintain MAP. The
decrease in MAP that is characteristic of HF, leads to the stimulation of the sympathetic nervous
system (SNS) and the release of catecholamines (4). Activation of the SNS results in increased
inotropy, chronotropy, and total peripheral resistance. Additionally, there is an activation of the
renin–angiotensin–aldosterone system (RAAS), that leads to increased concentrations of renin,
plasma angiotensin II, and aldosterone. Angiotensin II is a potent vasoconstrictor that has
important effects on cardiac myocytes and may contribute to the endothelial dysfunction present
in HF (2). Aldosterone is responsible for sodium and water retention to increase blood volume.
Nonetheless, overstimulation by the SNS is associated with myocardial toxicity, ventricular
remodeling, myocyte apoptosis and hypertrophy (4).
Ventricular remodeling refers to the alterations in the size, shape, structure, and function
of the ventricle, because of chronic stress on the heart (2). Initially, these changes are compensatory
to increase ventricular volume. In addition, ventricular mass and myocardial wall thickness
increase to improve contractility. This remodeling process in HF is progressive leading to fibrosis,
myocardial apoptosis, and contractile impairments.
HFrEF
The pathophysiology of HFrEF is well-understood and most of the therapeutic
interventions available have proven effective for this HF subtype. The patterns of ventricular
remodeling in HFrEF involve LV eccentric hypertrophy, LV chamber dilation, and markedly
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reduced end-systolic elastance (10, 20). HFrEF typically develops in response to an accelerated
and a large-scale myocyte loss/dysfunction secondary to conditions such as acute myocardial
infarction (MI), genetic abnormalities, myocarditis, or toxin effects (20).
Patients who develop HFrEF are more likely to be male with a history of coronary artery
disease (CAD) and have a greater risk of dying from cardiovascular causes. The reduced systolic
function characteristic in these patients result in low CO that is unable to meet the metabolic
demands. Consequently, symptoms of fatigue and exercise intolerance become evident. Another
direct consequence of the reduced contractility is an increase in end-diastolic pressure. Then is
transferred to the pulmonary, portal, and peripheral circulation, resulting in extravasation of fluid
and subsequent edema (21).
HFpEF
The pathophysiology of HFpEF seems to be associated with an underlying
proinflammatory state that triggers a cascade of events causing increased cardiomyocyte stiffness
and increased ventricular wall stiffness (22). Several risk factors interact in a complex manner that
result in the presence of clinical symptoms such as dyspnea and fatigue on activity (14). HFpEF
involves abnormalities in left ventricular relaxation, with reduced ventricular compliance, leading
to the impairment of diastolic ventricular filling. Abnormalities that affect ventricular filling
include an increase in myocardial stiffness of the myocytes and extracellular collagen matrix,
infiltrative disorders, and abnormalities in the cardiac and systemic microvasculature. As a result,
it requires elevated filling pressures to obtain normal LV end-diastolic volumes (14, 15, 21).
Common causes include CAD, hypertension, hypertrophic cardiomyopathy, obesity, diabetes, and
chronic obstructive pulmonary disease (10, 14).
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HFpEF is characterized by concentric remodeling and LV hypertrophy, with small to
normal cavity volumes (14, 15, 20). Patients who develop HFpEF are more likely to be older,
female, and have a history of hypertension or atrial fibrillation (AF). HFpEF represents over half
of prevalent HF, however, regardless of the improvements in understanding the pathophysiology
of this entity, effective therapies are yet to be stablished (1, 14, 15, 22). A possible explanation is
that HFpEF is a heterogeneous condition consisting of several pathophysiological subtypes (23).
SUMMARY
Although HFrEF and HFpEF share similar signs, symptoms, and outcomes, they represent
two different disorders, with individual pathogenesis pathways. As such, they should be studied
and treated separately. In HFrEF, the usually patterns of ventricular remodeling involve LV
eccentric hypertrophy and LV chamber dilation whereas in HFpEF concentric remodeling and LV
hypertrophy with small to normal cavity volumes are common. However, it is important to note
that neither remodeling pattern is unique to just HFrEF or HFpEF. For example, concentric
hypertrophy has been also reported in a subset of patients with HFrEF. While HFrEF is associated
with a direct myocyte loss/dysfunction, HFpEF is associated with an underlying proinflammatory
state secondary to comorbid conditions. Identification of the underlying causes and
pathophysiology of HF subtypes is critical for therapeutic reasons, as the precise pathology
determines the specific treatment used.

RISK FACTORS
Several epidemiologic studies have examined the relationship between potential risk
factors and HF overall, HFrEF, and HFpEF (10, 24-27). Bui et al. (15) established major and minor

24

clinical risk factors for the development of HF. Among the major risk factors are age, male sex,
hypertension, LV hypertrophy, MI, valvular heart disease, obesity, and diabetes. Some of the
minor risk factors include smoking, dyslipidemia, chronic kidney disease, albuminuria, sedentary
lifestyle, and low socioeconomic status. Evidence suggests that identification and modification of
some of these potential risk factors may prevent or delay the development of HF (9).
McKee et al. (16) were among the first to report the influence of age and gender in HF
occurrence. They found that incidence rates of HF increased markedly with age and were higher
in men than in women at all ages. Recent reports estimate that by the age of 40, people in the U.S
have a one in five chance of developing HF and that it is more common in males until the age of
65 (9, 15).
African Americans have the highest prevalence of HF at 4.6 per 1000 person-years, mostly
related with the greater burden of atherosclerotic risk factors in this population. The prevalence of
HF in Hispanic, Caucasian, and Asian Americans is 3.5, 2.4, and 1.0 per 1000 person-years,
respectively (2). However, among a diverse sample of 39,578 participants from the Chicago Heart
Association Detection Project in Industry, the Atherosclerosis Risk in Communities (ARIC) study,
and the Cardiovascular Health Study, the lifetime risk for developing HF at age 45 years was 30
to 42% in white men, 20 to 29% in black men, 32 to 39% in white women, and 24 to 46% in black
women (12).
Hypertension is a significant risk factor for HF overall (28). About 75% of all HF patients
have preexisting hypertension and this risk factor alone doubles the risk of developing HF
compared to normotensive patients (2). Dunlay et al. (26) reported the frequency of risk factors
among 962 incident HF cases in Olmsted County. Hypertension was the most common (66%) and
accounted for 20% of HF cases in this population, with the greatest importance in women. Because
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of the high prevalence of hypertension, there is a great contribution to the population burden of
HF. The greater the elevation in blood pressure, the greater the risk of developing HF (15).
Growing evidence illustrates a causal link between diabetes and obesity with HF
independently of CAD and hypertension. Diabetes increases the risk of HF by approximately twofold in men and up to five-fold in women. The presence of obesity results in a two-fold higher risk
of HF after adjustment for related risk factors (13, 28).
The presence of CAD markedly increases the risk of developing HF and correspond to the
underlying etiology in up to 60 to 70% of patients with systolic dysfunction (28). He at al. (25)
studied 13,643 subjects from the National Health and Nutrition Examination Survey (NHANES)
and reported a relative risk for HF of 8.11 (95% confidence interval (CI) 6.95-9.46) among those
with CAD. Additionally, it is estimated that 36% of patients with prior MI will experience HF in
the subsequent 7-8 years (13, 15).
Smoking, low physical activity, and alcohol intake have also been linked to the
development of HF. In the Coronary Artery Surgery Study, smoking was associated with a 47%
increased risk of developing HF (15). Also, an inverse relationship between physical activity and
the risk of HF has been reported. Among subjects from NHANES, there was a 23% higher risk of
developing HF in those with low physical activity levels (25). Alcohol intake has a U-shaped
relationship with the risk of developing HF; greater amounts of alcohol intake have been associated
with the development of toxic cardiomyopathy (9).
New predictors of HF have been investigated including circulating biomarkers. In 2004,
Wang et al. (29) showed that levels of plasma NPs predicted future HF among 3,346 individuals.
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Those with B-type NP concentrations in the top quintile (>20 pg/mL in men, and >23.3 pg/mL in
women) had a three-fold increased risk of developing HF over five years (30).
Lloyd et al. (31) determined the lifetime risk for developing HF among Framingham Heart
Study (FHS) participants. At age 40 years, the lifetime risk for HF was 21.0% (95% CI 18.7% to
23.2%) for men and 20.3% (95% CI 18.2% to 22.5%) for women. For those in which HF occurred
in the absence of MI, the lifetime risk was 1 in 9 for men and 1 in 6 for women, respectively.
Mosterd et al. (13) compared different risk factors for the occurrence of HF from three
population-based studies, the FHS, the Cardiovascular Health Study, and the Rotterdam Study.
Among the risk factors included were hypertension, MI, angina pectoris, diabetes, LV
hypertrophy, valvular disease, AF, and chronic obstructive pulmonary disease (COPD). In the
FHS, the population attributable risk (PAR) of hypertension was 39% and 59% for men and
women, respectively. In the Cardiovascular Health Study, researchers found more than two-fold
increased risk of HF in those with LV hypertrophy with a PAR of 6%. In the Rotterdam Study, the
highest relative risk was associated with diabetes for men, and COPD for woman. In addition, they
reported that hypertensive women were 2.6 times more likely to develop HF that normotensive
women, but this was not seen in men (15).
When examining risk factors by HF subtype, Ho et al. (32) studied differences in clinical
predictors between HFrEF (EF ≤45%) and HFpEF (EF >45%) among participants from the FHS
(Table 2). They reported as independent predictors for HFrEF male sex, hypertension, higher heart
rate, prior cardiovascular disease (CVD), LV hypertrophy, and left bundle branch block (LBBB).
On the other hand, higher body mass index, smoking, and AF were independent predictors for
HFpEF.
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Table 2. Multivariable-adjusted risk factors of HFrEF and HFpEF
HFrEF
HFpEF
HR
95% CI
p value
HR
95% CI
p value
Demographics
Age, per year
1.08 (1.06-1.09) <0.001
1.13
(1.11-1.14) <0.001
Female
0.48 (0.37-0.63) <0.001
1.14
(0.85-1.53) 0.4
Clinical
Hypertension
1.76 (1.28-2.41) <0.001
Heart rate, per 12 bpm
1.32 (1.19-1.48) <0.001
Prior myocardial infarction 3.49 (2.48-4.90) <0.001
Prior coronary heart disease 1.73 (1.27-2.34) <0.001
Cerebrovascular disease
1.96 (1.34-2.86) <0.001
Diabetes mellitus
2.91 (2.21-3.85) <0.001
2.88
(2.05-4.05) <0.001
BMI, per 4.7 kg/m²
1.41
(1.23-1.61) <0.001
Current smoker
2.04
(1.39-2.99) <0.001
Valvular disease
2.44 (1.48-4.04) <0.001
4.88
(3.05-7.82) <0.001
ECG criteria
Atrial fibrillation
2.47
(1.57-3.89) <0.001
Left ventricular hypertrophy 2.73 (2.04-3.65) <0.001
Left bundle branch block
3.41 (1.78-6.52) <0.001
HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection
fraction; HR, hazard ratio; CI, confidence interval; bmp, beats per minute; BMI, body mass
index; kg, kilograms; m², meters squared.
Note. Adapted from “Predictors of new-onset heart failure: differences in preserved versus reduced
ejection fraction” by Ho et al. Circ Heart Fail. 2013; 6(2): 279-286.

Similarly, Lee et al. (33) reported that risk factors associated with an increased odds of
HFrEF were male sex, prior MI, and LBBB. Among risk factors associated with HFpEF were
female sex, elevated systolic blood pressure, and AF. Risk factors such as diabetes, smoking, and
hypertension, were associated with both HF subtypes.
Using Medicare data from individuals ≥65 years of age without HF, Lee at al. (10)
evaluated the relationship between different risk factors and HF subtypes, and the relative
influence (RI) of each predictor in the development of HFrEF and HFpEF. Male sex (hazard ratio

28

(HR) 2.07, 95% CI 1.81-2.37), cardiomyopathy (HR 4.37, 95% CI 3.21-5.97), and MI (HR 1.94,
95% CI 1.23-3.07) were strongly associated with HFrEF. Contrarily, pulmonary hypertension (HR
1.66, 95% CI 1.23-2.22) and AF (HR 2.02, 95% CI 1.80-2.26) were strongly associated with
HFpEF. Cardiomyopathy and AF had the highest RI for the development of HFrEF (20.7%) and
HFpEF (8.4%), respectively. Age and diabetes were associated with both HF subtypes, with age
being the strongest predictor with a RI >35%.
Further research of the interaction between risk factors and the development of HF
subtypes, will not only improve the diagnosis and treatment of individuals with HF, but also allow
prevention strategies to be more effective in reducing the burden of HF (15).

HEART FAILURE AND ENDOTHELIAL DYSFUNCTION
Endothelial dysfunction has received increasing attention and a considerable amount of
studies have been carried out to investigate its association with HF. Evidence indicates that
endothelial dysfunction may play a role in the pathogenesis and progression of HF (6, 34, 35). The
endothelium plays important physiological roles that involve regulation of blood vessel tone,
permeability, metabolism, and hemostasis. Abnormal endothelial function has been associated
with high oxidative stress and inflammation, that directly affects nitric oxide (NO) bioavailability
and promotes vascular dysfunction and plaque formation (36). Several factors such as smoking,
obesity, age, hypertension, hyperlipidemia, physical inactivity, and poor dietary habits, have been
identified to adversely affect the endothelium (37). It seems that impaired endothelial function is
the initial step in atherogenesis, which is consider an important factor in the development of CVD
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(38-40). Clinical manifestations of endothelial dysfunction include edema, hypertension, abnormal
vasoconstriction, and hypercoagulability.
NO is synthesized from L-arginine by NO synthase (NOS). Cardiac myocytes express two
types of NOS, endothelial NOS (eNOS) and inducible NOS (iNOS). Shear stress stimulate the
production of NO via the eNOS, while inflammatory cytokines does do so via the proinflammatory
iNOS. Disruption of NO contributes to systemic vasoconstriction and increases vascular stiffness
which are hallmarks in HF. As a result, there is an increase in left and right ventricular systolic
workload. In addition, the basal production of NO due to stimulation of iNOS is increased in
patients with HF. However, high concentrations of NO have been associated with myocyte injury
and reduced myocardial contractility. Contrarily, the reduced CO associated with HF, limits
endothelial shear stress which is responsible for the stimulation of eNOS expression. Downregulation of eNOS results in reduced NO bioavailability and consequently lower levels of
vasodilatory response (5, 6).
Several invasive and non-invasive techniques have been developed to evaluate endothelial
function. However, the gold standard to assess its function and its impairment continues to be
unclear (39). Flow-mediated dilation (FMD) is a common non-invasive tool for the assessment of
endothelial function/dysfunction that has shown to be accurate and reproducible, allowing for
repetition of measurements over time (39-41). It indirectly measures NO release in response to
shear stress due to reactive hyperemia. FMD relies on obtaining a baseline diameter of the artery
with ultrasound imaging before cuff inflation to supra-systolic pressure. Subsequent cuff deflation
induces reactive hyperemia with shear stress causing vasodilatation. The change in artery diameter
is then quantified as a percentage from the baseline diameter. However, FMD requires specialized
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and expensive equipment, as well as highly trained operators, and the technique is not standardized
(6, 42).
Agewall et al. (43) compared FMD in the brachial and radial arteries after reactive
hyperemia induced by forearm or upper-arm cuff occlusion in 24 healthy subjects. They found that
FMD was greater in the radial artery than in the brachial artery. It seems that FMD is greater in
smaller arteries maybe due to greater hyperemic shear stress in response to the same stimulus.
Also, they found that FMD of the brachial artery was significantly greater after upper-arm
occlusion compared to forearm occlusion, despite similar increases in blood flow. This may be
explained by the influence of other components not mediated by NO, most probably related to
local tissue ischemia (e.g., endothelial-derived hyperpolarizing factor, potassium, adenosine).
Similarly, Doshi et al. (42) compared cuff positions (wrist or upper arm occlusion) to
evaluate the NO component of brachial artery dilatation in 10 healthy males. They found that
dilatation was significantly greater after upper-arm occlusion and was only partially attenuated
after infusion of a NOS inhibitor. Contrarily, dilatation after wrist occlusion was abolished after
the infusion of the NOS inhibitor. They concluded that FMD of the brachial artery following
forearm occlusion was mediated exclusively by NO. For this reason, FMD following wrist
occlusion may be a more valid marker of endothelial function than dilatation following upper-arm
occlusion.
Several studies have shown that FMD is an independent predictor of future CVD events,
including HF. In addition, in HF patients a reduction in FMD has been shown to be an important
predictor of adverse outcomes associated with higher rates of hospitalization, and mortality (4446). The study of Ärnlöv et al. (35) revealed that individuals in the highest quartile of FMD had a
47% lower HF risk compared with individuals in the lowest quartile. In addition, they reported

31

lower risk according to higher FMD for HFrEF, but not for HFpEF (HR 0.79, 95% CI 0.64–0.97
vs. 0.99, 95% CI 0.78–1.26, respectively).
In a meta-analysis conducted by Ras et al. (47) they found an inverse association between
FMD and future CVD events, with a stronger relation in diseased populations. The overall CVD
risk was 0.92 (95%CI: 0.88; 0.95) per 1% higher FMD. Comparably, the meta-analysis of Inaba
et al. (48) reported a 15% lower risk of CVD events per 1% increase in brachial FMD.
A study conducted by Kishimoto et al. (34) revealed that individuals with HFpEF had
significantly smaller FMD values when compared with their healthy counterparts (2.9 ± 2.1% and
4.6 ± 2.7% p <0.001, respectively). Even after adjustment for age, sex, hypertension, dyslipidemia,
and diabetes, the relationship between FMD and HFpEF remained significant. In agreement, a
study among HFpEF patients showed lower brachial artery FMD values when compared to control
subjects (median 3.6% versus 7.2%, respectively). The relationship between brachial artery FMD
and HFpEF remained significant after adjustment for beta-adrenergic blockade, treatment with
loop diuretics therapy, and history of CAD (49).
Recent evidence suggests that reduced endothelium-dependent vasodilation in HF may be
a reflection of the underlying risk factors, rather than ventricular function in itself. Hashimoto et
al. (38) found that endothelial function was impaired according to the accumulation of risk factors.
FMD was significantly lower in those with one or more coronary risk factors when compared to
control subjects.
Endothelial dysfunction often accompanies diabetes and hypertension, both important risk
factors for HFpEF (23). These conditions cause oxidative stress with high levels of reactive oxygen
species that interfere with NO production in endothelial cells (50). Disruption of the NO signaling
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pathway can therefore explain the development of concentric LV remodeling, increased stiffness
of the cardiomyocyte, and increased collagen deposition in HFpEF subjects (23).
Atrial fibrillation which is another risk factor for HF especially in those with HFpEF, has
been associated with endothelial dysfunction. A study of 2,936 participants from MESA, revealed
an inverse relationship between FMD and AF. They reported that for 1-standard deviation (SD)
increase in FMD (2.8%) there was a 16% lower risk of AF (HR=0.84, 95% CI 0.70-0.99),
suggesting a role for endothelial dysfunction in AF pathogenesis (51).
An alternate option to the traditional FMD is total brachial artery reactivity (TBAR), a
noninvasive measurement that evaluates endothelial function using ultrasound imaging. This
measurement uses a baseline brachial artery diameter following cuff deflation instead of before
cuff inflation. It compensates for the absence of a stereotactic device, limiting the errors associated
with ultrasound probe displacement (52). Although the measurement process is different from
FMD, they might be comparable and equivalent. Ostrem et al. (40) compared pre-occlusion,
occlusion, and post-occlusion baseline brachial artery measurements on the calculation of FMD in
418 children and 533 adults. They found non-significant differences between the three baseline
measurements of brachial artery diameter. Additionally, peak FMD values were not significantly
different when calculated from pre-occlusion, occlusion or post-occlusion baseline diameters in
both, children and adults.
Polak et al. (52) evaluated whether TBAR was associated with first time coronary heart
disease (CHD) events among participants of MESA. Increased TBAR was associated with lower
risk of CHD events with a HR of 0.78 per SD increase (9.7 SD; p=0.001). Those participants with
TBAR above the median of 7.87% had a 31% lower risk of CHD events (HR 0.69; 95% C.I. 0.550.87; p=0.001). They found TBAR to be an independent predictor of incident CHD events.
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SUMMARY
In summary, evidence suggests that endothelial dysfunction may contribute to the
pathogenesis and maintenance of HF and may be a potential target for new therapeutic
development. Nonetheless, the questions about whether endothelial dysfunction, assessed by
TBAR, is of difference importance among HF subtypes, and whether it is a cause or a consequence
remain unanswered. Determining the relationship between endothelial dysfunction measured by
TBAR and incident HF subtypes may help to elucidate a better understanding of the complex
syndrome that is HF. This may contribute to the establishment of guidelines that recommend
clinically testing endothelial function in addition to traditional risk factors.
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The purpose of this study was to investigate whether total brachial artery reactivity (TBAR)
is associated with overall incident heart failure (HF) and the two HF sub-types, heart failure with
reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), in a
diverse population-based sample of U.S. adults. This chapter provides the details of the
methodology used to address the research question.

DATA COLLECTION
The Multi-Ethnic Study of Atherosclerosis (MESA) is an ongoing, multicenter, prospective
cohort study of cardiovascular disease (CVD) sponsored by the National Heart Lung and Blood
Institute of the National Institutes of Health. Specific information on the MESA protocol has been
described elsewhere (1), and additional information can be found at https://www.mesa-nhlbi.org/.
The MESA study a diverse, population-based sample of 6,814 men and women (45-84 years of
age), with no clinical CVD history at baseline. The cohort includes Caucasian (38%), African
American (28%), Hispanic (22%), and Asian (12%) participants recruited from six field centers
across the United States between July 2000 and August 2002:
1. University of California, Los Angeles, CA
2. University of Minnesota, St. Paul, MN
3. Northwestern University, Chicago, IL
4. Wake Forest University, Winston-Salem, NC
5. John Hopkins University, Baltimore, MD
6. Columbia University, New York, NY
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Eligibility status was determined from self-reported information. MESA’s exclusion criteria
included:
1. Age younger than 45 or older than 84 years
2. Physician-diagnosed:
a. Heart attack
b. Angina or taking nitroglycerin
c. Stroke or transient ischemic attack
d. Heart failure
3. Current atrial fibrillation
4. Having undergone procedures related to CVD
5. Active treatment for cancer
6. Pregnancy
7. Any serious medical condition which would prevent long-term participation
8. Weight >300 pounds
9. Cognitive inability as judged by the interviewer
10. Living in a nursing home or on the waiting list for a nursing home
11. Plans to leave the community within five years
12. Language barrier (speaks other than English, Spanish, Cantonese or Mandarin)
13. Chest CT scan in the past year
Six additional exams have been completed since 2000, and participants are contacted every
nine to 12 months to assess clinical morbidity and mortality. For the present study, the sample
included 5,499 participants (45-84 years of age) with available brachial artery endothelial function
assessed by ultrasound at the baseline visit.
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The present study was reviewed and approved by the Institutional Review Board of the
University of North Florida (Appendix A). Data from the MESA was requested and obtained from
the National Institutes of Health/ National Heart, Lung, and Blood Institute: Biologic Specimen
and Data Repository Information Coordinating Center (2).

PRIMARY DEPENDENT VARIABLE
The primary outcome was time to congestive heart failure (TTCHF) defined as the number
of days from enrollment to congestive heart failure (CHF) event. CHF was an adjudicated event
classified as ‘Definite’, ‘Probable’, or ‘Absent’. MESA identified possible HF events in both
inpatient and outpatient mainly by participant self-report via follow-up calls, notification at clinic
visits, or directly to the field center. Other means of identifying HF events included a search in the
National Death Index (NDI), obituaries, or other public notice. At least two physicians reviewed
medical records and death certificates, interviews, questionnaires, and other procedures of the
eligible events to assign a final classification. Probable HF required the presence of HF symptoms,
a physician diagnosis of HF, and evidence of the patient receiving medical treatment for HF such
as diuretics, digitalis, vasodilators, beta-blockers, or ACE inhibitors. Definite HF required the
same criteria as probable HF and one or more of the following criteria:
1. Pulmonary edema/congestion by chest x-ray.
2. Dilated ventricle or poor left ventricular function by echocardiography or
ventriculography.
3. Evidence of left ventricular diastolic dysfunction.
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Those who did not meet any criteria or only had a physician diagnosis of HF but without
any treatment or evidence on imaging were classified as absent. Disagreement or conflicting
endpoint diagnosis were assigned to a third reviewer, or if necessary, to the MESA morbidity and
mortality committee for the final decision. For those participants with a final classification of HF,
ejection fraction (EF) was recorded either as a percent or classified as ‘Normal’, ‘Low’, or
‘Unknown’. For this study, incident HF overall included participants with either definite or
probable HF, independent of EF. Participants with EF ≤40% or classified as ‘Low’ were
considered HFrEF, and those with EF ≥50% or classified as ‘Normal’ were considered HFpEF.

PRIMARY INDEPENDENT VARIABLE
The primary independent variable in this study was TBAR1, defined as the total brachial
artery reactivity as a percent (%) value attained by ultrasound imaging. Participant preparation
included abstaining from food and caffeine for six hours prior to the brachial artery endothelial
function assessment. If necessary, a small snack, mostly carbohydrates and no fat content, was
provided 90 minutes prior to the assessment. Consumption of vitamin E or C in the six hours before
the procedure was discouraged, and the participant should not have smoked any cigarettes (3).
Blood pressure was then obtained in both the right and left arms using the automated
sphygmomanometer (Dinamap®, Tampa, FL).
Trained technicians at each of the six field centers acquired B-mode ultrasound images
with a Logiq-700 ultrasound device (GE Healthcare, Waukesha, WI) and an ultrasound transducer
(M12L) set at 9 MHz, without the use of a stereotactic holder. Participants were in a supine position
during the examination with the right arm supported at the elbow and wrist. The ultrasound probe
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was placed on the right arm’s medial aspect a few centimeters above the elbow with a slight
angulation to best visualize the brachial artery. An occlusion cuff was placed on the upper right
forearm just below the antecubital fossa and inflated to a pressure of 200 mmHg when the baseline
SBP was <150 mmHg, or 50 mmHg above maximal systolic pressure when the baseline SBP was
>150 mmHg but, <180 mmHg. The cuff was kept inflated for five minutes with the ultrasound
probe held centered over the same brachial artery segment. Images were videotaped and recorded
using super VHS tapes, starting 15 seconds before cuff deflation, and continuing for 90 seconds
after cuff release.
Images were sent to Tufts Medical Center Ultrasound Reading Center for blinded
processing. Digital streams of the brachial artery ultrasound images were acquired from the
videotapes at a frame-rate of 30 frames-per-second as MJPEG compressed images (compression
ratio six to one) using a Pinnacle DC-30 Video board (Corel Inc., Mountain View CA) and a
Compaq AP-200 workstation (Compaq Computer Corporation, Houston, TX) equipped with a
Pentium III processor (Intel Corporation, Santa Clara, CA). A reader reviewed the images and
identified the point at which the blood pressure cuff had been released. The reader then identified
an appropriate brachial artery segment and placed a rectangular region of interest on a selected
image frame (Figure 1).
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Fig. 1 Segment of the brachial artery. From “MESA manual of operations: field center and
laboratory procedures” by O’Leary D. H. [cited 2021 January].

Customized software was used to calculate the location of the near and far wall mediaadventitia interfaces in this region of interest and to generate brachial artery diameter versus time
curves without manual editing. These were transferred to Access (Microsoft, Redmond WA)
databases for archiving. The archived brachial artery diameter curves were subsequently retrieved
and processed using a MATLAB (The MathWorks Inc., Natick MA) program that smoothed the
diameter versus time curves using a finite impulse response digital filter and processed the
resultant curves to identify the maximum diameter and time to maximum diameter starting 20
seconds following the release of the blood pressure cuff. The algorithm then searched for a
minimum diameter going backwards until 10 seconds after cuff release based on previous
observations.
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Then TBAR was calculated as:
TBAR (%) = (maximum diameter – minimum diameter) x 100
(minimum diameter)
Although 5,499 brachial diameter curves were processed, there were 765 instances where
the curve analysis algorithm detected a maximum diameter in a time window 20 to 30 seconds
after cuff release and failed to find a smaller diameter in the preceding time interval. These cases
likely represented low amplitude responses and were assigned a 0% TBAR value (4).
A dichotomous TBAR variable was created based on the median value (below or above
7.9%). Analysis in this study was performed after excluding potential TBAR outliers. We set two
limits, a minimum value at 0% and a maximum value at the 99th percentile (40.9%).

OTHER INDEPENDENT VARIABLES
The potential confounding variables that were controlled for in this study include the
following:
AGE
Age was self-reported on the personal history form at exam one. This was included in the
analysis as a continuous variable.
SEX
Sex was self-reported on the personal history form at exam one as either male or female.
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RACE/ETHNICITY
Race was self-reported as either Caucasian, African American, Hispanic, or Asian.
SMOKING
Smoking status was self-reported on the personal history form at exam one and was a
created variable. Participants were classified as never smokers, former smokers, or current
smokers. Those who answered “yes” to the question, “Have you smoked cigarettes in the past 30
days?” were considered current smokers. Those who answered “no” to having smoked cigarettes
in the past 30 days but “yes” to the question, “Have you smoked at least 100 cigarettes in your
lifetime?” were considered former smokers. Those who answered “no” to having smoked at least
100 cigarettes in their lifetime and “no” to having smoked cigarettes in the past 30 days were
considered never smokers.
BODY MASS INDEX
Body mass index (BMI) was calculated as body weight in kilograms (kg) divided by the
height in meter squared (m²) using measurements obtained at exam one. The four BMI categories
used in this study included normal (<25 kg/m²), overweight (≥25 - <30 kg/m²), obese (≥30 - ≤40
kg/m²), and extreme obese (>40 kg/m²).
BLOOD PRESSURE
Blood pressure was measured in the seated position using a Dinamap Monitor Pro 100®
(Critikon, Tampa, Florida, USA) automated oscillometric device; pressures were the average of
the last two of three performed measurements. Blood pressure was categorized into three groups
according to the most recent blood pressure recommendations by the American Heart Association
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(5): normal (SBP <120 mmHg and DBP < 80 mmHg), elevated (SBP 120-129 mmHg and DBP
<80 mmHg), and hypertensive (SBP ≥130 mmHg or DBP ≥80 mmHg). Participants who reported
using antihypertensive medications were also considered as being hypertensive.
LOW-DENSITY LIPOPROTEIN CHOLESTEROL
The low-density lipoprotein cholesterol (LDL-C) was calculated using the formula of
Friedewald et al. (6). In MESA, it was a created variable and was categorized according to the
National Cholesterol Education Program Guidelines (NCEP) (7). LDL-C values ≥130 mg/dL were
classified as elevated. Additionally, lipid-lowering medication use was self-reported on the
medications form at exam one and confirmed during the medication interview. Participants taking
lipid-lowering medications were also classified as having elevated LDL-C.
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL
The high-density lipoprotein cholesterol (HDL-C) was measured in EDTA plasma using
the cholesterol oxidase method (Roche Diagnostics) after precipitation of non-HDL-cholesterol
with magnesium/dextran. HDL-C was used to create a gender-stratified variable according to the
NCEP Guidelines (7). HDL-C values <50 mg/dL for females and <40 mg/dL for males were
classified as low. Participants taking lipid-lowering medications were also classified as having low
HDL-C.
TRIGLYCERIDES
Triglycerides were measured in EDTA plasma using Triglyceride GB reagent (Roche
Diagnostics, Indianapolis, IN 46250) on the Roche COBAS FARA centrifugal analyzer. In the
MESA, triglycerides were categorized according to the NCEP Guidelines (NCEP) (7).
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Triglyceride values ≥150 mg/dL were classified as elevated. Participants taking lipid-lowering
medications were also classified as having elevated triglycerides.
DIABETES
The presence of diabetes mellitus was based on self-reported physician diagnosis, use of
insulin or oral hypoglycemic medication, or a fasting glucose value ≥126 mg/dL (8). Those who
answered “yes” to the question, “Has a doctor ever told you that you had diabetes (sugar in the
blood)?” were considered as having diabetes. Those who answered “yes” to the question, “Are you
taking medicine (insulin or pills) for this?” were also considered as having diabetes. Serum glucose
was measured by rate reflectance spectrophotometry using thin-film adaptation of the glucose
oxidase method on the Vitros analyzer (Johnson & Johnson Clinical Diagnostics, Inc., Rochester,
NY 14650).
MYOCARDIAL INFARCTION
Identification of possible MI events in both inpatient and outpatient were made by
participant self-report via follow-up calls, notification at clinic visits, or directly to the field center.
Other means of identifying MI events included search in the NDI, obituaries, or other public notice.
At least two physicians reviewed each event’s case materials, and its data were analyzed by a
computer algorithm that used standardized criteria to assign a final classification. The criteria for
MI included information about chest pain, cardiac enzymes, and electrocardiogram. For the
analysis, we included only MI events that occurred before the first HF event.
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ATRIAL FIBRILLATION
AF was either self-reported or through review of in-hospital events records via the
International Classification of Diseases (ICD9) code (427.31: AF). For the analysis, we included
only AF events that occurred before the first HF event.

STATISTICAL ANALYSIS
The data in this study were managed using SAS 9.4 (SAS Institute Inc, Cary, NC) (9).
Variable recodes, data coding validation and analysis were conducted in SAS. Variables are
presented as means and standard deviation (SD) values if continuous and as percentages if
categorical. Descriptive characteristics were obtained using procedures PROC MEANS and PROC
FREQ for continuous and categorical variables, respectively. The procedure PROC
UNIVARIATE was used to calculate TBAR outliers. We set two limits, a minimum value at 0%
and a maximum value at the 99th percentile. A dichotomous TBAR variable was created based on
the median value (below or above 7.9%).
Separate proportional hazards regression models (PROC PHREG) were used to calculate
multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) to determine the risk
of HF overall, HFrEF, and HFpEF according to TBAR values. HF participants without EF data
were excluded from the subtype analyses. Three different models were created controlling for
known HF risk factors, including age, gender, race/ethnicity, BMI, diabetes, blood pressure, HDLC, LDL-C, triglycerides, smoking status, MI, and AF. Model 1 was unadjusted, model 2 was ageadjusted, and model 3 was fully adjusted. The level of significance was set at p = 0.05 for all tests.
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Additionally, using proportional hazards regression models, covariates included in the fully
adjusted model were chosen using a stepwise backward elimination process; covariates that did
not contribute significantly based on p = 0.05 were removed and excluded from the final analysis.
A final parsimonious model was included to elucidate the relationship between the independent
and dependent variables. Kaplan-Meier survival curves were plotted by the median value of TBAR
for overall HF, HFrEF, and HFpEF, using the life test procedure (PROC LIFETEST), and
compared statistically using the log-rank test.
Finally, we evaluated the effect of TBAR as a continuous variable (per 1 SD value of 9.7%)
on time to HF, using a cut point of 50% for EF. The analysis in this study included a whole sample
of 5,499 participants with available TBAR values. We also performed the analysis excluding the
765 curves with low amplitude responses for a full sample of 4,734 participants.

53

REFERENCES
1. Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study of Atherosclerosis: objectives
and design. Am J Epidemiol. 2002; 156(9):871-881.
2. National Institutes of Health/National Health Lung and Blood Institute: Biologic Specimen
and

Data

Repository

Information

Coordinating

Center.

In:

BIOLINCC.

https://biolincc.nhlbi.nih.gov/home/.
3. MESA Coordinating Center. MESA manual of operations: field center and laboratory
procedures.

[cited

2021

January].

Available

from

http://www.mesanhlbi.org/publicDocs/MesaMop/MesaMop1-5-01.doc.
4. Polak J, Ouyang P, Vaidya D. Total brachial artery reactivity and first time incident
coronary heart disease events in a longitudinal cohort study: The multi-ethnic study of
atherosclerosis. PLoS ONE. 2019; 14(4): e0211726.
5. Whelton PK, Carey RM, et al. 2017 Guideline for the prevention, detection, evaluation,
and management of high blood pressure in adults. JACC. 2018; 71(19): e127-248.
6. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density
lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin
Chem. 1972; 18: 499-502.
7. National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation,
and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;
285(19): 2486-97.
8. Genuth S, Alberti KGMM, Bennett P, et al. Follow-up report on the diagnosis of diabetes
mellitus. Diabetes Care. 2003; 26(11): 3160-7.

54

9. SAS Institute Inc. 2016. Base SAS® 9.4 Procedures Guide: Statistical Procedures, Sixth
Edition. Cary, NC: SAS Institute Inc.

55

Chapter Four: Manuscript

56

TOTAL BRACHIAL ARTERY REACTIVITY AND INCIDENT HEART FAILURE AND
HEART FAILURE SUB-TYPES: MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
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ABSTRACT
Background:

Endothelial dysfunction may be a phenotypic expression of heart failure
(HF). Total brachial artery reactivity (TBAR) is a non-invasive
measurement of endothelial function that has been associated with
increased risk of cardiovascular outcomes. Limited information is currently
available on the impact of TBAR on incident HF and its subtypes. The aim
of this study was to investigate whether TBAR is associated with overall
incident HF, and the two HF sub-types, HF with reduced ejection fraction
(HFrEF) and HF with preserved ejection fraction (HFpEF) in a communitybased study.

Methods:

Sample included 5,499 participants (45-84 years of age) from the MultiEthnic Study of Atherosclerosis who were free of cardiovascular disease at
baseline. Brachial artery was imaged via ultrasound after five minutes of
cuff occlusion at the right forearm. TBAR was calculated as the difference
between maximum and minimum brachial artery diameters following cuff
release, divided by the minimum diameter multiplied by 100%. A
dichotomous TBAR variable was created based on the median value (below
or above 7.9%). Participants with EF ≤40% were considered HFrEF and
those with EF ≥50% were considered HFpEF. Cox proportional hazards
regression models were used to calculate hazard ratios (HR) and 95%
confidence intervals (CI).

Results:

Over a mean follow-up period of 12.5 years, incident HF was diagnosed in
250 participants; 98 classified as HFrEF, 106 as HFpEF, and 46 with
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unknown or borderline EF (41-49%). Crude analysis revealed that those
with TBAR below the median had a significantly greater risk of HF (HR
1.46; 95% CI 1.13-1.88, p<0.01) and HFrEF (HR 1.61; 95% CI 1.07-2.43,
p<0.05). Following adjustment for known HF risk factors (e.g., age, sex,
race, blood pressure), these relationships were no longer statistically
significant. Borderline significant results were revealed in those with
HFpEF (HR 1.43; 95% CI 0.97-2.12, p=0.06). Kaplan-Meier curves suggest
significantly lower risks of developing HF and HFrEF in those with TBAR
above the median (log-rank p≤0.05 for both). When examined as a
continuous variable, with a cut point of 50% for EF, every 1-standard
deviation (9.7%) increase in TBAR resulted in a 19% and 29% decrease in
risk of HF (p<0.05) and HFrEF (p=0.05), respectively.
Conclusion:

Lower TBAR values were associated with higher rates of incident HF and
HFrEF, suggesting a possible role of endothelial dysfunction in HF
pathogenesis. The impact of other known HF risk factors may mediate this
relationship, thus further research is warranted.
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INTRODUCTION
Heart failure (HF) is a complex clinical syndrome that is associated with markedly altered
hemodynamic, neurohumoral, and peripheral vascular responses (1,2). The structural and
functional disturbances associated with HF affect the ability of the ventricles to deliver oxygenated
blood to tissues, resulting in significant morbidity, mortality, and healthcare expenses, especially
among those aged 65 and older (2,3). Based on systolic function measured by left ventricular
ejection fraction (LVEF), HF can be classified into two major subtypes: HF with reduced EF
(HFrEF), and HF with preserved EF (HFpEF). Despite the efforts to establish clear differences
between them, the etiology, pathophysiology, and effective treatments for HFpEF are still unclear
(12).
Heart failure affects 1-3% of the population worldwide and rises up to 10% and more in
populations over 70 years old (4). A recent report from the American Heart Association estimates
that 6.2 million adults in the United States have heart failure, and approximately half of those
events are characterized by reduced ejection fraction and the other half by preserved ejection
fraction (5). Although efforts to find effective treatment have reduced the prevalence of
rehospitalizations to 30-50%, the mortality rates remain high (4). In the Atherosclerosis Risk in
Communities study, the 30-day, 1-year, and 5-year case fatality rates after hospitalization for HF
were 10%, 22%, and 42%, respectively (29).
Endothelial dysfunction has been proposed as a phenotypic expression of HF as it may play
a role in its pathogenesis (5,6,34). The endothelium performs many vital physiological functions,
including regulation of blood vessel tone, permeability, hemostasis, as well as synthesis of vascular
growth factors (2,4,6). As a result, endothelial function has become critically important in the
assessment of cardiovascular diseases (CVD). The ability of blood vessels to vasodilate in

60

response to reactive hyperemia secondary to increased shear force requires a healthy endothelium.
This response is mediated by the production of nitric oxide (NO) via endothelial NO synthase
(eNOS). However, additional mechanisms such as increased concentrations of prostacyclin,
endothelium-derived hyperpolarizing factor, and ischemic metabolites may be involved in this
response (30). The disruption of NO production and delivery contributes to paradoxical
vasoconstriction, which is a hallmark in heart failure (6).
The brachial arteries respond to shear stress induced by increasing blood flow during
reactive hyperemia similar to the coronary arteries with a comparable blood vessel caliber. For this
reason, they can be used as a surrogate for coronary endothelial function (7,15). Total brachial
artery reactivity (TBAR) is a measure of endothelium-dependent vasodilation by ultrasound
imaging that indirectly measures NO release in response to shear stress. It relies on obtaining a
baseline diameter of the artery following cuff deflation (8). This method compensates for the
absence of a stereotactic device limiting the errors associated with ultrasound probe displacement.
Polak et al. (8) found TBAR to be an independent predictor of incident coronary heart disease
events. However, its association with incident HF and its subtypes in adults free of cardiovascular
diseases is currently unknown. Although endothelial dysfunction as measured by brachial flow‐
mediated dilation (FMD) has been associated with incident HF, in particular HFrEF (34), less is
known about its role in the development of HFpEF.
The aim of the present study was to investigate whether TBAR is associated with overall
incident HF and the two HF sub-types, HF with reduced EF (HFrEF), and HF with preserved EF
(HFpEF) in a community-based study of the Multi-Ethnic Study of Atherosclerosis (MESA). We
hypothesized that TBAR would be inversely related with incident HF and both HF subtypes.
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METHODS
Study design and population
The data for this study came from MESA (9), a continuous, multicenter prospective cohort
study of CVD sponsored by the National Heart Lung and Blood Institute of the National Institutes
of Health. MESA is a diverse, population-based sample of 6,814 men and women aged 45-84, with
no history of clinical CVD at baseline (10). The cohort includes Caucasian, African American,
Hispanic, and Asian participants recruited from six field centers across the United States between
July 2000 and August 2002. Six additional exams have been completed since 2000, and
participants are contacted every 9 to 12 months to assess clinical morbidity and mortality. Specific
information on the MESA protocol has been described elsewhere (9, 10, 11), and additional
information can be found at https://www.mesa-nhlbi.org/.
For the present study, the sample included 5,499 participants (45-84 years of age) with
available brachial artery endothelial function assessed by ultrasound at the baseline visit (Exam
1). Exclusions included individuals with systolic blood pressures (SBP) >180 mmHg, a blood
pressure difference between both arms ≥15 mmHg that may be indicative of subclavian stenosis,
individuals with previous radical mastectomy, congenital abnormality of the right hand or arm,
Raynaud’s phenomenon, and technical difficulties. Digital copies of brachial artery diameter
responses were not available in 623 cases, leading to 5,499 participants being analyzed (8). The
use of MESA data was approved by the Institutional Review Board of the University of North
Florida.
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Total brachial artery reactivity
Participants preparation included abstaining from food and caffeine for six hours prior to
the brachial artery endothelial function assessment. If necessary, a small snack, mostly
carbohydrates and no fat content was provided 90 minutes prior to the assessment. Consumption
of vitamin C or E in the six hours before the procedure was discouraged, and the participant should
not have smoked any cigarettes in the last six hours (11). Blood pressure was then obtained in both
the right and left arms using the automated sphygmomanometer Dinamap Monitor Pro 100®
(Critikon, Tampa, FL).
Trained technicians at each of the six field centers acquired B-mode ultrasound images
with a Logiq-700 ultrasound device (GE Healthcare, Waukesha, WI) and an ultrasound transducer
(M12L) set at 9 MHz, without the use of a stereotactic holder. Participants were in a supine position
during the examination with the right arm supported at the elbow and wrist. The ultrasound probe
was placed on the medial aspect of the right arm a few centimeters above the antecubital fossa
with a slight angulation to best visualize the brachial artery. An occlusion cuff was placed on the
upper right forearm just below the antecubital fossa and inflated to a pressure of 200 mmHg when
the baseline SBP was <150 mmHg, or 50 mmHg above maximal systolic pressure when the
baseline SBP was >150 mmHg but <180 mmHg. The cuff was kept inflated for five minutes with
the ultrasound probe held centered over the same brachial artery segment. Images were videotaped
and recorded using super VHS tapes, starting 15 seconds before cuff deflation, and continuing for
90 seconds after cuff release.
Images were sent to Tufts Medical Center Ultrasound Reading Center for blinded
processing. Digital streams of the brachial artery ultrasound images were acquired from the
videotapes at a frame-rate of 30 frames-per-second as MJPEG compressed images (compression
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ratio six to one) using a Pinnacle DC-30 Video board (Corel Inc., Mountain View CA) and a
Compaq AP-200 workstation (Compaq Computer Corporation, Houston, TX) equipped with a
Pentium III processor (Intel Corporation, Santa Clara, CA). A reader reviewed the images and
identified the point at which the blood pressure cuff had been released. The reader then identified
an appropriate brachial artery segment and placed a rectangular region of interest on a selected
image frame. Customized software was used to calculate the location of the near and far wall
media-adventitia interfaces in this region of interest and to generate brachial artery diameter versus
time curves without manual editing. These were transferred to Access (Microsoft, Redmond WA)
databases for archiving. The archived brachial artery diameter curves were subsequently retrieved
and processed using a MATLAB (The MathWorks Inc., Natick MA) program that smoothed the
diameter versus time curves using a finite impulse response digital filter and processed the
resultant curves to identify the maximum diameter and time to maximum diameter starting 20
seconds following release of the blood pressure cuff. The algorithm then searched for a minimum
diameter going backwards until 10 seconds after cuff release based on previous observations. Then
TBAR was calculated as:
TBAR (%) = (maximum diameter – minimum diameter) x 100
(minimum diameter)

Although 5,499 brachial diameter curves were processed, there were 765 instances where
the curve analysis algorithm detected a maximum diameter in a time window 20 to 30 seconds
after cuff release and failed to find a smaller diameter in the preceding time interval. These cases
likely represented low amplitude responses and were assigned a 0% TBAR value as previously
described (8).
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Heart failure
Participants were contacted by telephone every six to nine months after the baseline MESA
exam to determine whether any medical events have occurred. MESA identifies HF events in both
inpatient and outpatient through participant self-report via follow-up calls, notification at clinic
visits or directly to the field center. At least two physicians review medical records and death
certificates of the eligible events to assign a final classification. HF events can be classified as
‘Definite’, ‘Probable’, or ‘Absent’. Probable HF requires the presence of HF symptoms, a
physician diagnosis of HF, and evidence of the patient receiving medical treatment such as
diuretics, vasodilators, beta-blockers, or ACE inhibitors. Definite HF requires the same criteria as
probable HF, and one or more of the following criterion: pulmonary edema/congestion, dilated
ventricle or poor left ventricular function, or evidence of left ventricular diastolic dysfunction.
Those with only HF diagnosis without any treatment or evidence on imaging are classified as
absent. Disagreement or conflicting endpoint diagnosis are assigned to a third reviewer, or if
necessary, to the MESA morbidity and mortality committee for the final decision. For those
participants with a final classification of HF, ejection fraction is recorded either as a percent or
classified as ‘Normal’, ‘Low’, or ‘Unknown’. For this study, incident HF overall included
participants with either definite or probable HF, independent of ejection fraction. Participants with
EF ≤40% or classified as ‘Low’ were considered HFrEF, and those with EF ≥50% or classified as
‘Normal’ were considered HFpEF.
Covariates
Age, sex, race/ethnicity, smoking status, and medical history were self-reported during the
baseline MESA exam. The smoking status classified participants as never smokers, former
smokers, or current smokers (smoking cigarettes in the last 30 days). Body mass index (BMI) was
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calculated as body weight in kilograms (kg) divided by height in meter squared (m²). The four
BMI categories used in this study included normal (<25 kg/ m²), overweight (≥25 - <30 kg/ m²),
obese (≥30 - ≤40 kg/ m²), and extreme obese (>40 kg/ m²). Blood pressure was measured in the
seated position using a Dinamap Monitor Pro 100® (Critikon, Tampa, FL) automated
oscillometric device. Blood pressures were the average of the last two of three performed
measurements and were categorized in three groups: normal (SBP <120 mmHg and DBP <80
mmHg), elevated (SBP 120-129 mmHg and DBP <80 mmHg), and hypertensive (SBP ≥130
mmHg or DBP ≥80 mmHg). Participants who reported using antihypertensive medications were
also considered as being hypertensive. Lipids and lipoproteins categories were determined using
the National Cholesterol Education Program 2001 Guidelines (13). Triglyceride values ≥150
mg/dL and low-density lipoprotein cholesterol (LDL-C) values ≥130 mg/dL were classified as
elevated. High-density lipoprotein cholesterol (HDL-C) values <50 mg/dL for females and <40
mg/dL for males were classified as low. Participants who reported using lipid-lowering
medications were also considered as having elevated lipid levels. Waist circumference values ≥88
cm for females and ≥102 cm for males were considered as being at risk. The presence of diabetes
mellitus was based on self-reported physician diagnosis, use of insulin or oral hypoglycemic
medication, or a fasting glucose value ≥126 mg/dL. Myocardial infarction events that occurred
after baseline were self-reported at clinic visits, directly to the field center, or through interim
follow-up telephone calls. In addition, events were identified through review and abstraction of
medical records and death certificates. Atrial fibrillation diagnosis was self-reported or through
review of in-hospital events records via the International Classification of Diseases (ICD9) code
(427.31: AF) during follow-up.
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Statistical analyses
The data in this study were managed using SAS 9.4 (SAS Institute Inc, Cary, NC) (14).
Variables recodes, data coding validation, and analysis were conducted in SAS. Variables are
presented as means and standard deviation (SD) if continuous and as percentages if categorical. A
dichotomous TBAR variable was created based on the median value of the entire sample at
baseline (below or above 7.9%). Analysis was performed after excluding potential TBAR outliers.
We set two limits, a minimum value at 0%, and a maximum value at the 99th percentile (40.9%).
Cox proportional hazards regression models were used to calculate multivariable adjusted hazard
ratios (HRs) and 95% confidence intervals (CI) to determine the risk of HF overall, HFrEF, and
HFpEF according to TBAR values. Heart failure participants without EF data were excluded from
the subtype analyses. Three different models were created controlling for known HF risk factors
including age, sex, race/ethnicity, BMI, diabetes, blood pressure, HDL-C, LDL-C, triglycerides,
smoking status, myocardial infarction, and atrial fibrillation. Model 1 was unadjusted, model 2
was age-adjusted, and model 3 fully adjusted. The level of significance was set at p=0.05 for all
tests. Additionally, using proportional hazards regression, covariates included in the fully adjusted
model were chosen using a stepwise backward elimination process; covariates that did not
contribute significantly based on p=0.05 were removed and excluded from the final analysis. A
final parsimonious model was included to elucidate the relationship between the independent and
dependent variables. Kaplan-Meier survival curves were plotted by the median value of TBAR for
HF overall, HFrEF, and HFpEF, and compared statistically using the log rank test. Finally, we
evaluated the effect of TBAR as a continuous variable (per 1 SD value of 9.7%) on time to HF,
using a cut point of 50% for EF. The analysis in this study included the whole sample of 5,499

67

participants with available TBAR values. We also performed the analysis excluding the 765 curves
with low amplitude responses for a full sample of 4,734 participants (data not shown).

RESULTS
Of the 5,499 participants with available TBAR values, over a mean follow-up period of
12.5 years, incident HF was diagnosed in 250 participants; 98 classified as HFrEF, 106 as HFpEF,
and 46 with unknown or borderline EF (41-49%). Sample characteristics by HF subtypes are
shown in Table 1.
Table 1. Baseline characteristics of adults with and without heart failure by subtype
Total (n=5,499)
Total

Overall HF
n (%)
250 (4.5)

HFrEF
n (%)
98 (48)

HFpEF
n (%)
106 (52)

No HF
n (%)
5,249 (95.5)

Age, Mean (SD)

68.2 (8.93)

67.4 (9.19)

68.9 (9.08)

61.7 (10.18)

Male

151 (60.4)

70 (71.4)

57 (53.8)

2,548 (48.5)

Female

99 (39.6)

28 (28.6)

49 (46.2)

2,701 (51.5)

Caucasian

98 (39.2)

38 (38.8)

42 (39.6)

1,898 (36.2)

Asian

22 (8.8)

2 (2.0)

13 (12.3)

714 (13.6)

African American

77 (30.8)

36 (36.7)

29 (27.4)

1,452 (27.7)

Hispanic

53 (21.2)

22 (22.5)

22 (20.8)

1,185 (22.6)

Normal

50 (20.0)

22 (22.5)

22 (20.8)

1,579 (30.1)

Overweight

108 (43.2)

42 (42.9)

46 (43.4)

2,070 (39.4)

Obese

80 (32.0)

31 (31.6)

33 (31.1)

1,441 (27.5)

Extreme Obese

12 (4.8)

3 (3.1)

5 (4.7)

159 (3.0)

Sex

Race/Ethnicity

BMI
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Blood pressure
Normal

29 (11.6)

15 (15.3)

9 (8.5)

1,804 (34.4)

Elevated

17 (6.8)

5 (5.1)

11 (10.4)

434 (8.3)

Hypertensive

204 (81.6)

78 (79.6)

86 (81.1)

3,011 (57.4)

Never Smoked

111 (44.4)

42 (42.9)

43 (40.6)

2,698 (51.4)

Former Smoker

106 (42.4)

39 (39.8)

49 (46.2)

1,897 (36.1)

Current Smoker

33 (13.2)

17 (17.4)

14 (13.2)

654 (12.5)

Elevated LDL-C

110 (44.0)

44 (44.9)

46 (43.4)

2,393 (45.6)

Elevated TG

118 (47.2)

42 (42.9)

50 (47.2)

2,047 (39.0)

Low HDL-C

127 (50.8)

50 (51.0)

46 (43.4)

2,409 (45.9)

Healthy

93 (37.2)

43 (43.9)

35 (33.0)

2,542 (48.4)

At risk

157 (62.8)

55 (56.1)

71 (67.0)

2,707 (51.6)

No

177 (70.8)

75 (76.5)

72 (67.9)

4,608 (87.8)

Yes

73 (29.2)

23 (23.5)

34 (32.1)

640 (12.2)

≥7.9

100 (40.0)

37 (37.8)

43 (40.6)

2,595 (49.4)

<7.9

150 (60.0)

61 (62.2)

63 (59.4)

2,654 (50.6)

No

221 (88.4)

88 (89.8)

94 (88.7)

5,116 (97.5)

Yes

29 (11.6)

10 (10.2)

12 (11.3)

133 (2.5)

No

210 (84.0)

87 (88.8)

83 (78.3)

5,026 (95.8)

Yes

40 (16.0)

11 (11.2)

23 (21.7)

223 (4.2)

Smoking Status

Lipid/Lipoprotein

WC

Diabetes

TBAR

MI

AF
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HF, heart failure; HFrEF, heart failure with reduced ejection fraction (EF ≤ 40% or ‘Low’);
HFpEF, heart failure with preserved ejection fraction (EF ≥ 50% or ‘Normal'); BMI, body mass
index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein
cholesterol; TG, triglycerides; WC, waist circumference; TBAR, total brachial artery reactivity;
MI, myocardial infarction; AF, atrial fibrillation.
*HF participants with unknown or borderline EF (41-49%) were excluded from the subtype
analyses (n=46).

The participants with HF were significantly older than those without HF (p<0.001). The
prevalence of HF overall and HFrEF were higher in males (p<0.001) than in females, but the same
was not seen in those with HFpEF. Additionally, there was a greater proportion of diabetes,
hypertension, myocardial infarction, and atrial fibrillation in those with HF, regardless of subtype
(p<0.01). The proportion of participants with waist circumference values considered at risk was
significantly greater in those with HF and HFpEF (p<0.01). There was a slightly but significantly
greater proportion of TBAR values below the median in those with HF and HFrEF (p<0.01 and
p<0.05, respectively). However, there were no significant differences between the mean values of
TBAR for HFrEF and HFpEF (8.09±6.60 vs 8.56±7.79, p=0.64, respectively).
Risk of Heart Failure
The results of the multivariable adjusted model using the proportional hazard regression
procedure for HF overall are shown in Table 2. Crude analysis revealed that those with TBAR
below the median (7.9%) had significantly higher risk of HF (HR 1.46; 95% CI 1.13-1.88, p<0.01).
In the age-adjusted model, the risk of HF was attenuated but remained statistically significant (HR
1.30; 95% CI 1.01-1.68, p<0.05). However, in the fully adjusted model, these relationships were
no longer significant (p=0.79).
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Table 2. Hazard ratios (HR) associated with total brachial artery reactivity <7.9% and risk of
incident heart failure
Heart Failure Overall (n=250)
Model

HR

95% CI

1

1.46**

1.13-1.88

2

1.30*

1.01-1.68

3

1.23

0.95-1.59

Model 1: unadjusted; model 2: adjusted by age; model 3: adjusted by sex, race/ethnicity, BMI,
diabetes, blood pressure, HDL-C, LDL-C, triglycerides, smoking status, myocardial infarction,
and atrial fibrillation. CI, confidence interval. **p<0.01; *p<0.05.

Table 3 shows the HRs of HF overall in the parsimonious model. In this sample, from all
the covariates, sex, diabetes, blood pressure, myocardial infarction, and atrial fibrillation were
significantly associated with incident HF. Males had a significantly higher risk of HF overall
compared with females (HR 1.42; 95% CI 1.10-1.84, p<0.01). Having diabetes, elevated blood
pressure or being hypertensive resulted in more than twice elevated risk of HF. The presence of a
previous event of myocardial infarction or atrial fibrillation resulted in a two to three-time greater
risk of HF overall (HR 2.98; 95% CI 2.01-4.44 and HR 3.07; 95% CI 2.18-4.34, p<0.001,
respectively).

71

Table 3. Hazard ratios (HR) associated with risk of incident heart failure in the parsimonious
model
Heart Failure Overall (n=250)
HR

95% CI

Sex (male)

1.42*

1.10-1.84

Diabetes (yes)

2.48**

1.88-3.28

Elevated

2.34*

1.28-4.26

Hypertensive

3.49**

2.36-5.18

MI (yes)

2.98**

2.01-4.44

AF (yes)

3.07**

2.18-4.34

Blood pressure
Normal

MI, myocardial infarction; AF, atrial fibrillation; CI, confidence interval. **p<0.001; *p<0.01.

Figure 1 displays the Kaplan-Meier Survival curve showing the likelihood of remaining
HF free with time according to TBAR values. Results indicate significantly lower risk of
developing HF in those with TBAR above the median (log-rank p<0.05). When examining TBAR
as a continuous variable, every 1-standard deviation (9.7%) increase in TBAR resulted in a 19%
decrease in risk of HF overall (p<0.05). This corresponds to a 2% decrease in risk for each percent
increase in TBAR. Similar results were obtained when we repeated the analysis excluding the 765
curves with low amplitude responses (data not shown).
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Figure 1. Kaplan-Meier Survival curves showing the likelihood of remaining heart failure free

Survival Probability

with time according to total brachial artery reactivity values

Log-Rank p<0.05

Time to Heart Failure (Days)
*TBAR, total brachial artery reactivity.

Risk of Heart Failure with Reduced Ejection Fraction
Table 4 displays the results of the proportional hazard regression analyses for HFrEF.
Crude analysis revealed that those with TBAR below the median had a significantly greater risk
of HFrEF (HR 1.61; 95% CI 1.07-2.43, p<0.05). In the age-adjusted model, the risk of HFrEF was
attenuated and was borderline significant (p=0.06). In the fully adjusted model, these relationships
did not reach significance.
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Table 4. Hazard ratios (HR) associated with total brachial artery reactivity <7.9% and risk of
incident heart failure with reduced ejection fraction
HFrEF (n=98)
Model

HR

95% CI

1

1.61*

1.07-2.43

2

1.46

0.97-2.20

3

1.36

0.90-2.07

Model 1: unadjusted; model 2: adjusted by age; model 3: adjusted by sex, race/ethnicity, BMI,
diabetes, blood pressure, HDL-C, LDL-C, triglycerides, smoking status, myocardial infarction,
and atrial fibrillation. CI, confidence interval. *p<0.05.

Table 5 shows the HRs of HFrEF in the parsimonious model. Diabetes, sex, race/ethnicity,
blood pressure, myocardial infarction, and atrial fibrillation were significantly associated with
incident HFrEF. Males had significantly greater risk of HFrEF compared with females (HR 2.40;
95% CI 1.54-3.75, p<0.001). Although there was a 10% greater risk of HFrEF in African
Americans, the results were not statistically significant. Having diabetes was associated with a
greater risk of HFrEF and being hypertensive at baseline resulted in more than a two-fold increase
in risk of HFrEF (p<0.01). The presence of a previous event of myocardial infarction or atrial
fibrillation resulted in a two-time greater risk of HFrEF.
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Table 5. Hazard ratios (HR) associated with risk of incident heart failure with reduced ejection
fraction in the parsimonious model
HFrEF (n=98)
HR

95% CI

Sex (male)

2.40***

1.54-3.75

Diabetes (yes)

1.87**

1.14-3.05

African A.

1.10

0.69-1.77

Asian

0.14**

0.03-0.60

Hispanic

0.84

0.49-1.46

Elevated

1.32

0.48-3.63

Hypertensive

2.58**

1.46-4.53

MI (yes)

2.71**

1.38-5.31

AF (yes)

2.06*

1.08-3.91

Race/ethnicity
Caucasian

Blood pressure
Normal

African A., African Americans; MI, myocardial infarction; AF, atrial fibrillation; CI, confidence
interval. ***p<0.001; **p<0.01; *p<0.05.

Figure 2 displays the Kaplan-Meier Survival curve showing the likelihood of remaining
HFrEF free with time according to TBAR values. Results indicate significantly lower risk of
developing HFrEF in those with TBAR above the median (log-rank p=0.05). When examining
TBAR as a continuous variable, with a cut point of 50% for EF, every 1-standard deviation (9.7%)
increase in TBAR resulted in a 29% decrease in risk of HFrEF (p=0.05). This corresponds to a 3%
decrease in risk for each percent increase in TBAR.

75

Figure 2. Kaplan-Meier Survival curves showing the likelihood of remaining heart failure with

Survival Probability

reduced ejection fraction free with time according to total brachial artery reactivity values

Log-Rank p=0.05

Time to Heart Failure (Days)
*TBAR, total brachial artery reactivity.

Risk of Heart Failure with Preserved Ejection Fraction
Table 6 displays the results of the proportional hazard regression procedure for HFpEF.
Crude analysis revealed borderline significant results in those with HFpEF (HR 1.43; 95% CI 0.972.12, p=0.06).
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Table 6. Hazard ratios (HR) associated with total brachial artery reactivity <7.9% and risk of
incident heart failure with preserved ejection fraction
HFpEF (n=106)
Model

HR

95% CI

1

1.43*

0.97-2.12

2

1.28

0.86-1.88

3

1.19

0.80-1.77

Model 1: unadjusted; model 2: adjusted by age; model 3: adjusted by sex, race/ethnicity, BMI,
diabetes, blood pressure, HDL-C, LDL-C, triglycerides, smoking status, myocardial infarction,
and atrial fibrillation. CI, confidence interval. *p=0.06.

Table 7 shows the HRs of HFpEF in the parsimonious model. Diabetes, blood pressure,
myocardial infarction, and atrial fibrillation were significantly associated with incident HFpEF.
Having diabetes was associated with more than two-fold increase in the risk of HFpEF (HR 2.92;
95% CI 1.93-4.42, p<0.001). Those who had elevated blood pressure or were hypertensive at
baseline showed a four-fold greater risk of HFpEF (p<0.001). The presence of a previous event of
myocardial infarction or atrial fibrillation resulted in a three to four-fold greater risk of HFpEF.
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Table 7. Hazard ratios (HR) associated with risk of incident heart failure with preserved
ejection fraction in the parsimonious model
HFpEF (n=106)

Diabetes (yes)

HR

95% CI

2.92*

1.93-4.42

Blood pressure
Normal
Elevated

4.80*

1.98-11.59

Hypertensive

4.60*

2.30-9.20

MI (yes)

3.00*

1.63-5.51

AF (yes)

4.71*

2.94-7.54

MI, myocardial infarction; AF, atrial fibrillation; CI, confidence interval. *p<0.001.

Figure 3 displays the Kaplan-Meier Survival curve showing the likelihood of remaining
HFpEF free with time according to TBAR values. Results suggest a borderline significant lower
risk of developing HFpEF in those with TBAR above the median (log-rank p=0.06). When
examining TBAR as a continuous variable, results did not reach statistically significance.
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Figure 3. Kaplan-Meier Survival curves showing the likelihood of remaining heart failure with
preserved ejection fraction free with time according to total brachial artery reactivity values

DISCUSSION
In this population-based study, lower TBAR values were associated with higher rates of
incident HF and HFrEF, and borderline significant findings were revealed in those with HFpEF.
Furthermore, when examined as a continuous variable, every 1-SD (9.7%) increase in TBAR
resulted in a 19% and 29% decrease in risk of HF (p<0.05) and HFrEF (p=0.05), respectively.
These findings suggest a possible role of endothelial dysfunction in HF pathogenesis and add to
the evidence demonstrating that assessment of endothelial function is essential in diagnosis and
treatment of cardiovascular disease (2, 4, 6, 31).
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Noninvasive assessment of endothelial function is commonly conducted using the
traditional FMD technique. Several studies have found an association between endothelial
dysfunction measured by FMD and incident cardiovascular disease (CVD) events (7, 16, 17, 18).
The MESA study conducted by Yeboah et al. (18), demonstrated that endothelial dysfunction
measured by FMD of the brachial artery is associated with a higher rate of incident adverse CVD
events during a five-year follow-up period. The meta-analysis of Inaba et al. (6) involving 5,547
participants, found that impairment of brachial FMD is significantly associated with future CVD
events. The pooled relative risks of CVD events per 1% increase in brachial FMD following
adjustment for confounding risk factors was 0.87, corresponding to a 13% lower risk.
A uniqueness of the present study was the use of TBAR, that relies on baseline brachial
artery diameters obtained after the release of a blood pressure occlusion cuff, and its association
with incident HF and its subtypes. Although the measurement process is different from the
traditional FMD, they might be comparable and equivalent. Ostrem et al. (19) compared preocclusion, occlusion, and post-occlusion baseline brachial artery measurements on the calculation
of FMD in 418 children and 533 adults. They found no significant differences between the three
baseline measurements of brachial artery diameter. Additionally, peak FMD values were not
significantly different when calculated from pre-occlusion, occlusion or post-occlusion baseline
diameters in both children and adults. In agreement, Polak et al. (8) compared TBAR and FMD
data from MESA and found statistical equivalence between them.
Our findings are in agreement with the previous study of Ärnlöv et al. (34) using FMD as
a predictor of incident HF. This study revealed that individuals in the highest quartile of FMD had
a 47% lower HF risk compared with individuals in the lowest quartile. When analyzing by HF
subtypes, they reported lower risk for HFrEF in those individuals with higher FMD values, but the
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same was not seen in those with HFpEF (HR 0.79, 95% CI 0.64–0.97 vs. 0.99, 95% CI 0.78–1.26,
respectively). Similarly, Polak et al. (8) reported that increased TBAR values were associated with
lower risk of incident coronary heart disease (CHD) events with a HR of 0.78 per SD increase. In
addition, they found that a TBAR above the median of 7.87% was associated with a 31% lower
risk of CHD events (HR 0.69; 95% CI 0.55-0.87, p=0.001).
Although we found significantly greater risk of HF and HFrEF, and borderline significant
higher risk of HFpEF in those with TBAR below the median, these relationships were no longer
statistically significant following adjustment for known HF risk factors. These results suggest that
some coronary risk factors are independently related to impaired endothelial function and they
may mediate this relationship. Several studies have examined the association between coronary
risk factors and impaired endothelial function. Hashimoto et al. (21) found that endothelial
function in subjects without coronary risk factors (i.e., hyperlipidemia, diabetes, hypertension, and
cigarette smoking) was significantly greater than that in subjects with one or more risk factors.
Endothelial dysfunction appears to result from reduced levels of NO bioavailability largely related
to baseline coronary risk factors (31). This association is attributed to high oxidative stress
characterized by an increase in reactive oxygen species that scavenge and degrade available NO
within the vascular wall, and inflammation (22, 15).
Parsimonious models in this study indicated that diabetes, hypertension, myocardial
infarction, and atrial fibrillation were significantly associated with incident HF, HFrEF, and
HFpEF. Male sex was associated with higher risk of HF and HFrEF, but not with HFpEF. Lee et
al. (12) evaluated the differential impact of various demographic characteristics and comorbid
conditions on the development of HFrEF and HFpEF among Medicare beneficiaries. The most
influential predictors for HFrEF were male sex, diabetes, and myocardial infarction; and for
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HFpEF atrial fibrillation and diabetes were the most influential comorbidities (relative influence
of 8.4% and 5.6%, respectively). Similarly, the risk of HF was three-times greater in those with
CHD and two-times greater in those with diabetes (20). The population attributable risk was
highest for CHD with a greater proportion in men, and hypertension with a greater proportion in
women. Celermajer et al. (23) reported that in 238 subjects with no known cardiovascular risk
factors aging is associated with progressive endothelial dysfunction. The decline appears to occur
earlier in men than in women, with a steep decline in women around the time of the menopause
(0.21%/year after 40s, and 0.49%/year after the early 50s, respectively). Paniagua et al. (24) found
that hypertensive patients had significant impairment of FMD when compared with healthy
controls. In contrast, the same was not true for hypercholesterolemic patients. Diabetes has largely
been associated with endothelial dysfunction; it seems that the mechanisms behind this association
are related with inflammation, insulin-resistance, and hyperglycemia (25, 26). In a study of 2,936
participants from MESA, O’neal et al. (27) reported that lower FMD values were associated with
increased rates of atrial fibrillation, suggesting a potential role of endothelial dysfunction in its
pathogenesis.
The current study is not without limitations. The sample size was relatively small for those
with HF, HFrEF and HFpEF, limiting the generalizability of the results. This may have contributed
to the borderline significant results observed in HFpEF. It is possible that with a greater sample
size, the association between TBAR and HFpEF would have reached statistically significance. In
this context, it should be emphasized that TBAR and EF were measured at a single time point.
Changes in FMD may be more valuable in risk stratifying than relying in a single FMD
measurement at a given point in time (28). In the present study, TBAR was obtained at one visit.
In addition, incident HF was defined as time to first HF event, resulting in the exclusion of
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subsequent HF events with potential changes in EF over time. TBAR was measured with an
occlusion cuff placed proximal to the ultrasound probe (upper right forearm), which may indicate
that the vasodilatory response is not mediated exclusively by NO. Increased blood flow and shear
stress secondary to reactive hyperemia can stimulate vasorelaxation by different mechanisms
including increased concentrations of prostacyclin, endothelium-derived hyperpolarizing factor,
and ischemic metabolites (30). Doshi et al. (32) found that dilation was significantly greater after
upper arm occlusion when compared with wrist occlusion. In addition, during intra-arterial
infusion of NO synthase inhibitor, dilatation after upper arm occlusion was partially attenuated
(from 11.62±3.17% to 7.51±2.34%; p<0.006), whereas dilation after wrist occlusion was abolished
(from 7.25±2.49% to 0.16±2.24%; p<0.001). They concluded that dilatation after upper arm
occlusion has a substantial component not mediated by NO, most probably related to tissue
ischemia around the brachial artery. However, a study conducted by Vogel et al. (33) found that
subjects with and without risk factors (hypercholesterolemia, hypertension, cigarette smoking) are
better differentiated regarding endothelial function using the upper arm occlusion when compared
to lower arm occlusion. A possible explanation for this, is that vasodilation is greater using the
upper arm occlusion as a result of an increased hyperemic flow-mediated stimulation.
In conclusion, the present study demonstrated that lower TBAR values are associated with
higher rates of incident HF and HFrEF, and borderline significance with HFpEF, indicating a
possible role of endothelial dysfunction in HF pathogenesis. The impact of other known HF risk
factors may mediate this relationship, thus further research with a greater and more heterogenous
sample of adults free of CVD is warranted. It is critical to continue validating findings regarding
differences in risk factors leading to HFpEF and HFrEF.
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